Projects / Antibodies in immune-mediated diseases / Neuromyelitis optica

Evaluation of new immunological targets in neuromyelitis optica (NMO)


In collaboration with:

Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, and LINC, Université de Strasbourg-CNRS,  France

Jérôme de Seze and Élisabeth Trifilieff

Toscana Biomarkers S.r.l. Via Fiorentina,  Siena; Italy

Maria C. Alcaro and Ilaria Paolini

In NMO, an autoimmune disease of the central nervous system, anti-aquaporin 4 antibodies are currently the only available immunological markers, although they are not detected in 10–50% of patients. Using enzyme-linked immunosorbent assays, we evaluated the reactivity against 19 structurally defined peptides in 26 NMO sera compared with 21 healthy subjects. We observed increased levels of IgG against the myelin basic protein sequence MBP(156–175), the pyruvate dehydrogenase sequence PDH(167–186), and the N-glucosylated beta-turn peptide CSF114(Glc), the last of these having a possible correlation with onset of inflammatory relapse. These preliminary results may suggest that the aquaporin 4 is not the unique target in NMO and that the study of reactivity against these peptides would be helpful for the diagnosis and follow-up of the disease.


IgG response in NMO and NBD sera against peptides